- Home
- CRDL vs XTKG Comparison
CRDL vs XTKG Comparison
Compare CRDL & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- XTKG
- Stock Information
- Founded
- CRDL 2017
- XTKG 1997
- Country
- CRDL Canada
- XTKG Singapore
- Employees
- CRDL N/A
- XTKG N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- XTKG
- Sector
- CRDL Health Care
- XTKG
- Exchange
- CRDL Nasdaq
- XTKG NYSE
- Market Cap
- CRDL 104.5M
- XTKG 18.9M
- IPO Year
- CRDL N/A
- XTKG 2019
- Fundamental
- Price
- CRDL $1.23
- XTKG $1.10
- Analyst Decision
- CRDL Strong Buy
- XTKG
- Analyst Count
- CRDL 3
- XTKG 0
- Target Price
- CRDL $9.00
- XTKG N/A
- AVG Volume (30 Days)
- CRDL 328.6K
- XTKG 220.7K
- Earning Date
- CRDL 11-14-2024
- XTKG 11-27-2024
- Dividend Yield
- CRDL N/A
- XTKG N/A
- EPS Growth
- CRDL N/A
- XTKG N/A
- EPS
- CRDL N/A
- XTKG N/A
- Revenue
- CRDL N/A
- XTKG $15,234,138.00
- Revenue This Year
- CRDL N/A
- XTKG N/A
- Revenue Next Year
- CRDL N/A
- XTKG N/A
- P/E Ratio
- CRDL N/A
- XTKG N/A
- Revenue Growth
- CRDL N/A
- XTKG 51.59
- 52 Week Low
- CRDL $0.96
- XTKG $0.08
- 52 Week High
- CRDL $3.12
- XTKG $2.14
- Technical
- Relative Strength Index (RSI)
- CRDL 34.19
- XTKG 50.01
- Support Level
- CRDL $1.21
- XTKG $1.07
- Resistance Level
- CRDL $1.30
- XTKG $1.38
- Average True Range (ATR)
- CRDL 0.09
- XTKG 0.18
- MACD
- CRDL 0.00
- XTKG -0.00
- Stochastic Oscillator
- CRDL 8.20
- XTKG 32.14
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.